| Original language | English |
|---|---|
| Pages (from-to) | 297-299 |
| Number of pages | 3 |
| Journal | Annals of Allergy, Asthma and Immunology |
| Volume | 126 |
| Issue number | 3 |
| DOIs | |
| State | Published - Mar 2021 |
Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver
}
In: Annals of Allergy, Asthma and Immunology, Vol. 126, No. 3, 03.2021, p. 297-299.
Research output: Contribution to journal › Article › peer-review
TY - JOUR
T1 - Type 2 inflammation in the sputum of adolescents with asthma
AU - Severe Asthma Research Program (SARP) Investigators
AU - Coverstone, Andrea M.
AU - Boomer, Jonathan S.
AU - Lew, Daphne
AU - Bacharier, Leonard B.
AU - Castro, Mario
N1 - Funding Information: Disclosures: The following companies have provided funding support for the longitudinal conduct of the study to the Severe Asthma Research Program, unrelated to this work: AstraZeneca, Boehringer-Ingelheim, Genentech, GlaxoSmithKline, Sanofi-Genzyme-Regeneron, and Teva. Dr Bacharier reports receiving personal fees from GlaxoSmithKline, Genentech/Novartis, Merck, DBV Technologies, Teva, Boehringer-Ingelheim, AstraZeneca, WebMD/Medscape, Sanofi/Regeneron, Vectura, and Circassia. Dr Castro reports receiving grant support from Sanofi-Genzyme-Regeneron for the conduct of the Severe Asthma Research Program extended longitudinal study; receiving university grant funding from the National Institutes of Health, American Lung Association, and Patient-Centered Outcomes Research Institute; receiving pharmaceutical grant funding from AstraZeneca, GlaxoSmithKline, Novartis, Pulmatrix, Sanofi-Aventis, and Shionogi; serving as a consultant for Genentech, Teva, Sanofi-Aventis, and Novartis; serving as a speaker for AstraZeneca, Genentech, GlaxoSmithKline, Regeneron, Sanofi, and Teva; and receiving royalties from Elsevier. The remaining authors have no conflicts of interest to report.Funding: Funding for this project was supported by the following grants: National Heart, Lung, and Blood Institute grant numbers U10 HL109172, U10 HL109164, U10 HL109152, U10 HL109250, U10 HL109168, U10 HL109086, U10 HL109146, and U10 HL109257 and National Center for Advancing Translational Sciences grant number 5UL1 TR000448. Funding Information: Funding: Funding for this project was supported by the following grants: National Heart, Lung, and Blood Institute grant numbers U10 HL109172 , U10 HL109164 , U10 HL109152 , U10 HL109250 , U10 HL109168 , U10 HL109086 , U10 HL109146 , and U10 HL109257 and National Center for Advancing Translational Sciences grant number 5UL1 TR000448.
PY - 2021/3
Y1 - 2021/3
UR - http://www.scopus.com/inward/record.url?scp=85098195697&partnerID=8YFLogxK
U2 - 10.1016/j.anai.2020.11.018
DO - 10.1016/j.anai.2020.11.018
M3 - Article
C2 - 33276117
AN - SCOPUS:85098195697
SN - 1081-1206
VL - 126
SP - 297
EP - 299
JO - Annals of Allergy, Asthma and Immunology
JF - Annals of Allergy, Asthma and Immunology
IS - 3
ER -